Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Zealand Pharma announces EU approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
GlobeNewswire, Inc.
Press release – No. 24 / 2026 Zealand Pharma announces EU approval of ZeydovioTM (glepaglutide) for the treatment of short bowel syndrome The approval marks the first major advancement in short bowel syndrome treatment in Europe in more than a...
Ascendis Pharma Reports Third Quarter 2026 Financial Results
GlobeNewswire, Inc.
Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH®, €59 million for SKYTROFA®, and €16 million for YUVIWEL® Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of...
Zealand Pharma Announces Financial Results for the First Nine Months of 2026
GlobeNewswire, Inc.
Company announcement – No. 56 / 2026 Zealand Pharma Announces Financial Results for the First Nine Months of 2026 Advancing at pace towards Metabolic Frontier 2030: petrelintide in Phase 3, survodutide moving towards regulatory filings, positive...
A New Hampshire Airman's journey through military medicine
DVIDS - Georgia
For Tech. Sgt. Casey Wachowiak, effective medical care begins with trust.
PharmAla Biotech Signs Supply and Data Agreement with Aalborg University Hospital for Danish Randomized Trial of MDMA-Assisted Treatment for Service-Related PTSD
GlobeNewswire, Inc.
TORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development and manufacturing of MDXX-class molecules, including...
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026, at...
Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits
GlobeNewswire, Inc.
Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with...
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
GlobeNewswire, Inc.
Press release – No. 23 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic...
Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
GlobeNewswire, Inc.
Publication in Nature Communications confirmed TG4050’s robust clinical proof of principle, with 100% DFS sustained after more than 3 years of follow-up in head and neck cancer (HNSCC) Expansion of the myvac® platform with the initiation of the...
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
GlobeNewswire, Inc.
Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11% increase with placebo Company...
Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results
GlobeNewswire, Inc.
Press Release – No. 22 / 2026 Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Copenhagen, Denmark, November 5, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
GlobeNewswire, Inc.
Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851 ongoing by Novo Conference call...
ESO Appoints Three Associate Chief Medical Officers Across EMS, Education and Trauma
GlobeNewswire, Inc.
AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ESO Solutions, Inc. (“ESO”), a leading data services and software provider for fire departments, EMS, hospitals, and government agencies, today announced the appointment of three associate chief...
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
GlobeNewswire, Inc.
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study Preclinical...
Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding €0.5 Billion
GlobeNewswire, Inc.
Agreement builds on customer’s long-term deal in new Yokohama facility for five commercial biologics programs, now allocating an additional six commercial programs to Copenhagen facility to consolidate high-volume, single-use biologics...
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
GlobeNewswire, Inc.
This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a...
Top 10 Wheel Hub Motor Manufacturers in 2026: Advancing Medical Device Mobility
EIN Presswire
A practical reference for buyers evaluating wheel hub motor manufacturers in 2026. CALIFORNIA, CA, UNITED STATES, October 29, 2026 /EINPresswire.com/ -- China, Oct. 29, 2026 — Medical mobility designers are narrowing wheel hub motor choices...
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
GlobeNewswire, Inc.
Company Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing the risk of death by 50% in patients with PD-L1...
Hong Kong Halts Poultry Imports From Denmark, Minnesota Over H5N1
MENAFN
(MENAFN) Hong Kong has moved to block poultry meat and poultry products from two outbreak zones, one in Denmark and one in the United States, as highly pathogenic bird flu spreads, according to a report by state media on Tuesday.
Hong Kong Halts Poultry Imports from Parts of Denmark, US
MENAFN
(MENAFN) Hong Kong has suspended imports of poultry meat and related products from specific areas of Denmark and the United States following outbreaks of bird flu, according to reports published Tuesday.
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.